| 12.62 1.77 (16.31%) | 04-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.35 |
1-year : | 19.09 |
| Resists | First : | 14 |
Second : | 16.35 |
| Pivot price | 11.17 |
|||
| Supports | First : | 11.39 |
Second : | 9.77 |
| MAs | MA(5) : | 11.51 |
MA(20) : | 11.32 |
| MA(100) : | 13.54  |
MA(250) : | 12.43 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 53.4 |
D(3) : | 51.1 |
| RSI | RSI(14): 57.7 |
|||
| 52-week | High : | 21.4 | Low : | 6.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ COEP ] has closed Bollinger Bands are 24.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.68 - 12.73 | 12.73 - 12.79 |
| Low: | 10.82 - 10.87 | 10.87 - 10.92 |
| Close: | 12.52 - 12.61 | 12.61 - 12.7 |
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Wed, 08 Apr 2026
Coeptis Wins Nasdaq Nod for Z Squared Merger Listing - TipRanks
Wed, 08 Apr 2026
Nasdaq clears Coeptis (COEP) post-merger Z Squared stock to trade as ZSQR - Stock Titan
Wed, 08 Apr 2026
Coeptis to List Post-Merger Common Stock as ZSQR on Nasdaq Global Market - TradingView
Tue, 07 Apr 2026
Coeptis Therapeutics: Z Squared to List on Nasdaq Under ZSQR, Effective Upon Merger Close - Moomoo
Tue, 07 Apr 2026
Nasdaq Approves Listing for Coeptis Therapeutics Holdings, Inc. Post-Merger with Z Squared Inc. - Quiver Quantitative
Tue, 07 Apr 2026
Nasdaq approves ZSQR listing, putting Coeptis merger on track for Q2 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 13.7 (%) |
| Held by Institutions | 9 (%) |
| Shares Short | 452 (K) |
| Shares Short P.Month | 481 (K) |
| EPS | -2.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.35 |
| Profit Margin | 0 % |
| Operating Margin | -230.7 % |
| Return on Assets (ttm) | -65.1 % |
| Return on Equity (ttm) | -137 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.18 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -1.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -4.5 |
| PEG Ratio | 0 |
| Price to Book value | 5.34 |
| Price to Sales | 57.71 |
| Price to Cash Flow | -9.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|